BRPI1014775A2 - tratamento ex vivo de distúrbios imunológicos com inibidores de pkc-teta - Google Patents

tratamento ex vivo de distúrbios imunológicos com inibidores de pkc-teta

Info

Publication number
BRPI1014775A2
BRPI1014775A2 BRPI1014775A BRPI1014775A BRPI1014775A2 BR PI1014775 A2 BRPI1014775 A2 BR PI1014775A2 BR PI1014775 A BRPI1014775 A BR PI1014775A BR PI1014775 A BRPI1014775 A BR PI1014775A BR PI1014775 A2 BRPI1014775 A2 BR PI1014775A2
Authority
BR
Brazil
Prior art keywords
pkc
immune disorders
vivo treatment
theta inhibitors
theta
Prior art date
Application number
BRPI1014775A
Other languages
English (en)
Inventor
Alexandra Zanin-Zhorov
Maryanne Brown
Michael Dustin
Original Assignee
Boehringer Ingelheim Int
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42332785&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1014775(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int, Univ New York filed Critical Boehringer Ingelheim Int
Publication of BRPI1014775A2 publication Critical patent/BRPI1014775A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
BRPI1014775A 2009-04-28 2010-04-28 tratamento ex vivo de distúrbios imunológicos com inibidores de pkc-teta BRPI1014775A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17323709P 2009-04-28 2009-04-28
PCT/US2010/032707 WO2010126967A1 (en) 2009-04-28 2010-04-28 Ex-vivo treatment of immunological disorders with pkc-theta inhibitors

Publications (1)

Publication Number Publication Date
BRPI1014775A2 true BRPI1014775A2 (pt) 2016-04-19

Family

ID=42332785

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1014775A BRPI1014775A2 (pt) 2009-04-28 2010-04-28 tratamento ex vivo de distúrbios imunológicos com inibidores de pkc-teta

Country Status (14)

Country Link
US (1) US20120196919A1 (pt)
EP (1) EP2445503A1 (pt)
JP (1) JP2012525403A (pt)
KR (1) KR20120005460A (pt)
CN (1) CN102421435A (pt)
AU (1) AU2010241701A1 (pt)
BR (1) BRPI1014775A2 (pt)
CA (1) CA2760305A1 (pt)
CL (1) CL2011002690A1 (pt)
EA (1) EA201101568A1 (pt)
IL (1) IL215939A0 (pt)
MX (1) MX2011011290A (pt)
NZ (1) NZ595331A (pt)
WO (1) WO2010126967A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102908690A (zh) 2007-08-31 2013-02-06 密执安州立大学董事会 选择性细胞隔离装置及其相关方法
JP5937003B2 (ja) * 2009-05-18 2016-06-22 セラコス・インコーポレイテッドＴｈｅｒａｋｏｓ， Ｉｎｃ． 免疫介在性疾患における臨床応用のための、抑制機能の高められた制御性ｔ細胞のエクスビボ増加方法
UY33473A (es) 2010-06-28 2012-01-31 Vertex Pharma Compuestos y métodos para el tratamiento o la prevencion de infecciones por flavivirus
EP2585448A1 (en) 2010-06-28 2013-05-01 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
AU2011292040A1 (en) 2010-08-17 2013-03-07 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of Flaviviridae viral infections
US20130288370A1 (en) 2010-10-15 2013-10-31 Cytopherx, Inc. Cytopheresis cartridges and use thereof
US20140186372A1 (en) * 2011-06-16 2014-07-03 La Jolla Institute For Allergy And Immunology Compositions targeting pkc-theta and uses and methods of treating pkc-theta pathologies, adverse immune responses and diseases
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
WO2013016492A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Thiophene compounds
CA2852220A1 (en) 2011-10-14 2013-07-18 Cytopherx, Inc. Cartridge and method for increasing myocardial function
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
DK2953634T3 (da) * 2013-02-07 2021-08-30 Massachusetts Gen Hospital Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler
WO2014134251A1 (en) 2013-02-28 2014-09-04 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
ES2694637T3 (es) 2014-11-21 2018-12-26 F2G Limited Agentes antifúngicos
CN115043943A (zh) 2015-05-15 2022-09-13 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
US10993959B2 (en) 2015-09-04 2021-05-04 Regents Of The University Of Minnesota Methods and compositions for increasing the suppressive function of regulatory T-cells (Tregs)
US11266730B2 (en) 2015-09-29 2022-03-08 The General Hospital Corporation Methods of treating and diagnosing disease using biomarkers for BCG therapy
KR102410778B1 (ko) 2016-05-13 2022-06-21 더 제너럴 하스피탈 코포레이션 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27487A1 (es) * 2001-10-17 2003-05-30 Boehringer Ingelheim Pharma Derivados de pirimidina, medicamentos que contienen estos compuestos, su empleo y procedimiento para su preparación
CA2505546A1 (en) * 2002-11-08 2004-05-27 Tolerrx, Inc. Molecules preferentially associated with effector t cells and methods of their use
WO2004067516A1 (en) * 2003-01-30 2004-08-12 Boehringer Ingelheim Pharmaceuticals, Inc. 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta
WO2006014482A1 (en) * 2004-07-08 2006-02-09 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of pkc-theta

Also Published As

Publication number Publication date
AU2010241701A1 (en) 2011-10-13
US20120196919A1 (en) 2012-08-02
IL215939A0 (en) 2012-01-31
KR20120005460A (ko) 2012-01-16
CL2011002690A1 (es) 2012-04-27
WO2010126967A1 (en) 2010-11-04
CN102421435A (zh) 2012-04-18
EP2445503A1 (en) 2012-05-02
MX2011011290A (es) 2012-02-13
EA201101568A1 (ru) 2012-05-30
NZ595331A (en) 2013-08-30
JP2012525403A (ja) 2012-10-22
CA2760305A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
BRPI1014775A2 (pt) tratamento ex vivo de distúrbios imunológicos com inibidores de pkc-teta
BR112012001325A2 (pt) tratamento de distúrbios do fígado com inibidaores de pi3k
HRP20181608T1 (hr) Korištenje inhibitora pde7 u liječenju bolesti kretanja
BRPI1015238A2 (pt) diamidas de azetidilina como inibidores de monoaciglicerol lipase
IL217901A0 (en) Treatment of bdnf-related disorders using laquninimod
DOP2012000114A (es) Inhibidor bromodominio de benzodiazepina
EP2385843A4 (en) TREATMENT OF MUZOSITIS WITH CALLICINE INHIBITORS
EP2512375A4 (en) EXPANSION DEVICE FOR TREATING VASCULAR PASSAGE PATHWAYS
DK2470722T3 (da) Drænlegeme
DOP2011000397A (es) Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a
BRPI1008744A2 (pt) hidrotratamento de caboidratos
GB0915515D0 (en) Treatment of vasculoproliferative conditions
UY33155A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa
IL206491A0 (en) Treatment of produce
DK2453858T3 (da) Fremgangsmåde
IL225896A0 (en) Treatment of mecp-2 related disorders
EP2455088A4 (en) INHIBITOR OF LIFT OF TRIGLYCERIDE RATE IN BLOOD
EP2488198A4 (en) TREATMENT AND DIAGNOSIS OF INFLAMMATORY DISORDERS
BR112012004071A2 (pt) tratamento de petróleo
GB0908101D0 (en) Treatment of stress
FR2948785B1 (fr) Terminateur de transaction
IL223385B (en) Treatment of inflammatory disorders
UY33136A (es) Tropinonabencilaminas como inhibidores de la beta-triptasa
FI20095315A (fi) Iskulaite
EP2440238A4 (en) Methods of Treatment

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.